Bicara Therapeutics Stock Forecast - Naive Prediction
| BCAX Stock | 17.59 0.62 3.65% |
The Naive Prediction forecasted value of Bicara Therapeutics Common on the next trading day is expected to be 17.94 with a mean absolute deviation of 0.56 and the sum of the absolute errors of 34.95. Bicara Stock Forecast is based on your current time horizon.
At this time, The RSI of Bicara Therapeutics' share price is at 51 suggesting that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling Bicara Therapeutics, making its price go up or down. Momentum 51
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.54) | EPS Estimate Current Year (2.48) | EPS Estimate Next Year (2.93) | Wall Street Target Price 30.7778 | EPS Estimate Current Quarter (0.53) |
Using Bicara Therapeutics hype-based prediction, you can estimate the value of Bicara Therapeutics Common from the perspective of Bicara Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Bicara Therapeutics using Bicara Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Bicara using crowd psychology based on the activity and movement of Bicara Therapeutics' stock price.
Bicara Therapeutics Implied Volatility | 1.66 |
Bicara Therapeutics' implied volatility exposes the market's sentiment of Bicara Therapeutics Common stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Bicara Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Bicara Therapeutics stock will not fluctuate a lot when Bicara Therapeutics' options are near their expiration.
The Naive Prediction forecasted value of Bicara Therapeutics Common on the next trading day is expected to be 17.94 with a mean absolute deviation of 0.56 and the sum of the absolute errors of 34.95. Bicara Therapeutics after-hype prediction price | USD 17.59 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Bicara Therapeutics to cross-verify your projections. Prediction based on Rule 16 of the current Bicara contract
Based on the Rule 16, the options market is currently suggesting that Bicara Therapeutics Common will have an average daily up or down price movement of about 0.1% per day over the life of the 2026-04-17 option contract. With Bicara Therapeutics trading at USD 17.59, that is roughly USD 0.0182 . If you think that the market is fully incorporating Bicara Therapeutics' daily price movement you should consider acquiring Bicara Therapeutics Common options at the current volatility level of 1.66%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-04-17 Bicara Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Bicara Therapeutics' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Bicara Therapeutics' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Bicara Therapeutics stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Bicara Therapeutics' open interest, investors have to compare it to Bicara Therapeutics' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Bicara Therapeutics is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Bicara. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Bicara Therapeutics Additional Predictive Modules
Most predictive techniques to examine Bicara price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Bicara using various technical indicators. When you analyze Bicara charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Bicara Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2010-12-31 | Previous Quarter 563.2 M | Current Value 591.3 M | Quarterly Volatility 215.2 M |
Bicara Therapeutics Naive Prediction Price Forecast For the 24th of January
Given 90 days horizon, the Naive Prediction forecasted value of Bicara Therapeutics Common on the next trading day is expected to be 17.94 with a mean absolute deviation of 0.56, mean absolute percentage error of 0.49, and the sum of the absolute errors of 34.95.Please note that although there have been many attempts to predict Bicara Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Bicara Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Bicara Therapeutics Stock Forecast Pattern
| Backtest Bicara Therapeutics | Bicara Therapeutics Price Prediction | Buy or Sell Advice |
Bicara Therapeutics Forecasted Value
In the context of forecasting Bicara Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Bicara Therapeutics' downside and upside margins for the forecasting period are 14.03 and 21.85, respectively. We have considered Bicara Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Bicara Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Bicara Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 119.2371 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.5638 |
| MAPE | Mean absolute percentage error | 0.0335 |
| SAE | Sum of the absolute errors | 34.9542 |
Predictive Modules for Bicara Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bicara Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bicara Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Bicara Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Bicara Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Bicara Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Bicara Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Bicara Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Bicara Therapeutics' historical news coverage. Bicara Therapeutics' after-hype downside and upside margins for the prediction period are 13.71 and 21.47, respectively. We have considered Bicara Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Bicara Therapeutics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Bicara Therapeutics is based on 3 months time horizon.
Bicara Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Bicara Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bicara Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Bicara Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.13 | 3.91 | 0.04 | 0.09 | 9 Events / Month | 8 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
17.59 | 17.59 | 0.00 |
|
Bicara Therapeutics Hype Timeline
Bicara Therapeutics is currently traded for 17.59. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of 0.09. Bicara is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.13%. %. The volatility of related hype on Bicara Therapeutics is about 574.16%, with the expected price after the next announcement by competition of 17.68. About 12.0% of the company shares are held by company insiders. The book value of Bicara Therapeutics was currently reported as 7.38. The company recorded earning per share (EPS) of 5.38. Bicara Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out Historical Fundamental Analysis of Bicara Therapeutics to cross-verify your projections.Bicara Therapeutics Related Hype Analysis
Having access to credible news sources related to Bicara Therapeutics' direct competition is more important than ever and may enhance your ability to predict Bicara Therapeutics' future price movements. Getting to know how Bicara Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Bicara Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| KURA | Kura Oncology | (0.06) | 16 per month | 0.00 | (0.03) | 6.59 | (5.05) | 22.27 | |
| SEPN | Septerna Common Stock | 1.92 | 10 per month | 2.85 | 0.06 | 7.41 | (5.00) | 27.95 | |
| EYPT | Eyepoint Pharmaceuticals | (0.05) | 4 per month | 3.09 | 0.12 | 7.21 | (4.80) | 20.13 | |
| PROK | ProKidney Corp | 2.47 | 24 per month | 0.00 | (0.09) | 6.82 | (8.95) | 25.70 | |
| PRME | Prime Medicine Common | (0.05) | 10 per month | 0.00 | (0.02) | 13.35 | (8.59) | 23.00 | |
| TNGX | Tango Therapeutics | (0.08) | 8 per month | 4.02 | 0.09 | 11.29 | (6.24) | 31.20 | |
| PHAT | Phathom Pharmaceuticals | (0.05) | 4 per month | 3.43 | 0.03 | 7.68 | (4.63) | 24.16 | |
| MRVI | Maravai Lifesciences Holdings | 0.09 | 8 per month | 3.17 | 0.05 | 8.38 | (6.35) | 20.24 | |
| SVRA | Savara Inc | 2.47 | 13 per month | 2.41 | 0.20 | 8.43 | (4.85) | 24.50 | |
| FTRE | Fortrea Holdings | 0.15 | 12 per month | 3.38 | 0.18 | 9.63 | (5.96) | 33.07 |
Other Forecasting Options for Bicara Therapeutics
For every potential investor in Bicara, whether a beginner or expert, Bicara Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Bicara Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Bicara. Basic forecasting techniques help filter out the noise by identifying Bicara Therapeutics' price trends.Bicara Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bicara Therapeutics stock to make a market-neutral strategy. Peer analysis of Bicara Therapeutics could also be used in its relative valuation, which is a method of valuing Bicara Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Bicara Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Bicara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bicara Therapeutics shares will generate the highest return on investment. By undertsting and applying Bicara Therapeutics stock market strength indicators, traders can identify Bicara Therapeutics Common entry and exit signals to maximize returns.
Bicara Therapeutics Risk Indicators
The analysis of Bicara Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Bicara Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting bicara stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.18 | |||
| Semi Deviation | 3.82 | |||
| Standard Deviation | 4.05 | |||
| Variance | 16.44 | |||
| Downside Variance | 15.03 | |||
| Semi Variance | 14.57 | |||
| Expected Short fall | (3.52) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Bicara Therapeutics
The number of cover stories for Bicara Therapeutics depends on current market conditions and Bicara Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Bicara Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Bicara Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Bicara Therapeutics Short Properties
Bicara Therapeutics' future price predictability will typically decrease when Bicara Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Bicara Therapeutics Common often depends not only on the future outlook of the potential Bicara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bicara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 54.4 M | |
| Cash And Short Term Investments | 489.7 M |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.